Delayed
Australian S.E.
22:52:04 2024-05-12 EDT
|
5-day change
|
1st Jan Change
|
0.068
AUD
|
-5.56%
|
|
-25.27%
|
+209.09%
|
Fiscal Period: June |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
19.14
|
49.92
|
21.06
|
4.368
|
Enterprise Value (EV)
1 |
14.34
|
36.17
|
10.25
|
0.6595
|
P/E ratio
|
-1.85
x
|
-10.6
x
|
-4.5
x
|
-0.56
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17,008,986
x
|
21,370,854
x
|
19,256,036
x
|
3,054,918
x
|
EV / Revenue
|
12,740,471
x
|
15,484,461
x
|
9,367,032
x
|
461,207
x
|
EV / EBITDA
|
-2.55
x
|
-10.2
x
|
-2.58
x
|
-0.08
x
|
EV / FCF
|
-5,940,428
x
|
-32,266,676
x
|
-6,817,981
x
|
-154,775
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
3.46
x
|
3.44
x
|
1.83
x
|
1.03
x
|
Nbr of stocks (in thousands)
|
109,384
|
156,009
|
156,009
|
156,009
|
Reference price
2 |
0.1750
|
0.3200
|
0.1350
|
0.0280
|
Announcement Date
|
20-09-07
|
21-08-30
|
22-08-29
|
23-08-28
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.4863
|
1.125
|
2.336
|
1.094
|
1.43
|
EBITDA
1 |
-2.182
|
-3.462
|
-5.632
|
-3.536
|
-3.967
|
-7.924
|
EBIT
1 |
-2.182
|
-3.464
|
-5.633
|
-3.538
|
-3.972
|
-7.931
|
Operating Margin
|
-
|
-712.18%
|
-500.55%
|
-151.44%
|
-363.17%
|
-554.62%
|
Earnings before Tax (EBT)
1 |
-2.416
|
-4.095
|
-5.774
|
-3.539
|
-3.96
|
-7.782
|
Net income
1 |
-2.416
|
-4.095
|
-5.774
|
-3.539
|
-3.96
|
-7.782
|
Net margin
|
-
|
-842.03%
|
-513.03%
|
-151.51%
|
-362.03%
|
-544.21%
|
EPS
|
-
|
-0.4095
|
-0.0948
|
-0.0303
|
-0.0300
|
-0.0500
|
Free Cash Flow
|
-
|
-1.133
|
-2.414
|
-1.121
|
-1.503
|
-4.261
|
FCF margin
|
-
|
-232.99%
|
-214.47%
|
-47.99%
|
-137.39%
|
-297.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-01-14
|
20-01-14
|
20-09-07
|
21-08-30
|
22-08-29
|
23-08-28
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.17
|
2.83
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
4.8
|
13.8
|
10.8
|
3.71
|
Leverage (Debt/EBITDA)
|
-0.0785
x
|
-0.8168
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-1.13
|
-2.41
|
-1.12
|
-1.5
|
-4.26
|
ROE (net income / shareholders' equity)
|
-
|
130%
|
-2,018%
|
-35.4%
|
-30.5%
|
-98.8%
|
ROA (Net income/ Total Assets)
|
-
|
-100%
|
-95%
|
-20.6%
|
-18.3%
|
-57.7%
|
Assets
1 |
-
|
4.08
|
6.076
|
17.15
|
21.67
|
13.49
|
Book Value Per Share
|
-
|
-0.5000
|
0.0500
|
0.0900
|
0.0700
|
0.0300
|
Cash Flow per Share
|
-
|
0.1100
|
0.0500
|
0.0900
|
0.0700
|
0.0200
|
Capex
1 |
0
|
0
|
0
|
0.01
|
0
|
-
|
Capex / Sales
|
-
|
0.09%
|
0.27%
|
0.21%
|
0.43%
|
-
|
Announcement Date
|
20-01-14
|
20-01-14
|
20-09-07
|
21-08-30
|
22-08-29
|
23-08-28
|
|
1st Jan change
|
Capi.
|
---|
| +209.09% | 8.53M | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|